Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company’s lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
Read more on News-Medical-Net